Orion is a globally operating Finnish developer of pharmaceuticals and diagnostic tests – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. It is continuously developing new drugs and treatment methods. The core therapy areas of Orion’s pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory for which Orion developes inhaled Easyhaler® pulmonary drugs. Orion’s pharmaceutical innovations are created within its R&D organisation. The organisation employs top professionals in the field of drug molecule development and optimisation. There are around 500 professionals working in R&D. Orion has offices in Espoo, Turku and Kuopio in Finland, and in Nottingham in England and Mumbai in India. In its own R&D, Orion focuses on early-phase drug development. Orion has launched several proprietary products onto the market in various therapy areas. In the initial and final stages of research projects Orion works together with skilled partners, such as universities and other pharmaceutical companies. The partnerships allow Orion to work on a large number of research projects simultaneously while focusing on its own core competence. Successful research also benefits our partners.